Kalshi to allow bets on clinical trials, FDA decisions

Kalshi, a prediction market platform, has launched betting on clinical trial outcomes and FDA regulatory decisions in partnership with AppliedXL, starting with late-stage trials and initial contracts including Gilead's anito-cel cancer drug and Summit Therapeutics' lung cancer drug. Traders are required to verify employment and cannot hold material nonpublic information.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.